Combating Public Health Threats for Communities Around the World Company Overview 44th Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our ...

Core Insights - Emergent BioSolutions reported strong financial performance in Q3 2025, exceeding revenue and adjusted EBITDA guidance, driven by growth in the naloxone segment and new contract modifications [7][12][30] - The company is focused on expanding its biodefense portfolio and enhancing international sales, which now represent 34% of its Medical Countermeasures (MCM) sales [25][28] Financial Performance - Q3 2025 revenues reached $231 million, surpassing the high end of guidance by $21 million, with a year-to-date net income of $107 million and earnings per share of $1.89 [11][12] - Adjusted EBITDA margin improved to 38%, reflecting operational efficiencies and a favorable product mix, with adjusted EBITDA guidance raised to $195 million to $210 million [14][22] - Total liquidity increased to $346 million, with net leverage improving to approximately 2x adjusted EBITDA, down from 3.3x in 2024 [8][19] Business Segments - The naloxone business remains a leader in the market, with a 13% increase in unit volume and a 9% revenue growth quarter over quarter [10][11] - The biodefense segment is diversified, addressing threats such as smallpox, anthrax, and Ebola, with significant government contracts secured [6][28] Strategic Initiatives - Emergent is actively pursuing growth through strategic investments in biodefense products and international collaborations, with a focus on enhancing its core business [20][29] - The company has initiated a $50 million share repurchase program and has repurchased 2.3 million shares year-to-date [21][30] Market Outlook - The company anticipates continued growth in the naloxone market and is well-positioned to capitalize on increasing international demand for its products [9][25] - Emergent's ongoing collaboration with the U.S. Government and international partners is expected to drive future revenue growth [23][28]

Core Viewpoint - Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501), a metronidazole oral suspension, and is actively pursuing funding opportunities to support its development programs and enhance its market position [2][3][14]. Group 1: Product Development and Market Position - LIKMEZ™ (ATI-1501) is the first FDA-approved, ready-to-use liquid oral suspension of metronidazole, specifically designed for patients who have difficulty swallowing tablets or are sensitive to taste [3][4]. - The re-launch of LIKMEZ follows new patent coverage extending to 2039, marking a significant milestone for the company and its partner, Saptalis Pharmaceuticals [2]. - Appili is focused on driving continued sales of LIKMEZ while advancing other product candidates, including ATI-1701 and ATI-1801 [3]. Group 2: Funding and Financial Performance - The company has submitted five non-dilutive funding proposals to the U.S. government, with a total potential value of up to US$125 million, aimed at supporting the development of critical infectious disease products [3][14]. - For the fiscal year ended March 31, 2025, Appili reported a net loss of CAD 2.6 million, which is an improvement from a net loss of CAD 3.8 million in the previous year, primarily due to increased government assistance and other income [19][20]. - As of March 31, 2025, the company had cash reserves of CAD 1.2 million, a significant increase from CAD 0.1 million a year earlier, indicating improved liquidity [21]. Group 3: Research and Development Progress - ATI-1701, a biodefense vaccine candidate for tularemia, has received approximately US$11.6 million in funding from the U.S. Air Force Academy and has shown promising results in providing protection against lethal tularemia [5][6]. - The company is actively pursuing additional funding and partnership opportunities for ATI-1801, a topical antiparasitic product that has received Orphan Drug Designation from the FDA [10][13]. - Appili has successfully completed technology transfer for the ATI-1701 manufacturing process, supporting future development activities [8].

Emergent BioSolutions (EBS) Conference Summary Company Overview - Emergent BioSolutions is a biopharma company with a focus on biodefense and medical countermeasures, established for over 25 years [2][3] - The company produces critical products for the U.S. Government and allied nations, including vaccines and therapeutics for smallpox, anthrax, Ebola, and botulism [3][4][22] Core Products and Market Position - Key products include: - Tymbexa (smallpox vaccine) - Sifendis (anthrax vaccine) - BioThrax (anthrax treatment) - Ibanga (Ebola treatment) - Narcan (opioid overdose reversal) [21][22][30] - Narcan is the largest product, with a market share of approximately 70-75% in the naloxone category [37] Financial Performance and Strategic Plan - Emergent aims for revenue between $750 million to $850 million and adjusted EBITDA of $150 million to $200 million for fiscal 2025 [43] - Adjusted EBITDA improved from negative in 2023 to $183 million in 2024, indicating a successful stabilization phase [14][43] - The company is currently in a turnaround phase, focusing on investments in R&D and business development to drive growth [15][41] Challenges and Opportunities - The company faced significant debt issues, which have been addressed through debt reduction and maturity extensions [9][12] - Emergent is working to enhance the accessibility of Narcan, aiming to include it in first aid kits and increase distribution through partnerships with retailers and e-commerce platforms [30][34][36] Regulatory and Market Environment - Emergent benefits from bipartisan support for biodefense initiatives, which is crucial for securing government contracts [20] - The company manufactures products in the U.S. and Canada, minimizing the impact of tariffs and aligning with reshoring trends in the pharmaceutical industry [48][50] Future Aspirations - The long-term goal is to transform Emergent into a sustainable growth company, with a focus on reducing opioid overdose deaths and expanding international market presence [57][58] - The company aims to leverage its CDMO capabilities to assist other pharmaceutical companies in bringing manufacturing back to the U.S. [51][53] Conclusion - Emergent BioSolutions is positioned to play a critical role in public health through its innovative products and strategic initiatives aimed at addressing pressing health threats, particularly in the context of opioid overdoses and biodefense [36][57]

Core Viewpoint - SIGA Technologies, Inc. has reported its financial results for Q1 2025, indicating a decline in product sales and total revenues compared to the same period in 2024, while also highlighting significant future sales expectations from government orders and international sales [2][3]. Financial Performance - Product sales for Q1 2025 were $5.8 million, down from $23.9 million in Q1 2024, representing a decrease of approximately 75.8% [3]. - Total revenues decreased to $7.0 million in Q1 2025 from $25.4 million in Q1 2024, a decline of about 72.5% [3]. - The company reported an operating loss of $2.3 million for Q1 2025, compared to an operating income of $11.3 million in Q1 2024 [3]. - Net loss for Q1 2025 was $0.4 million, a significant drop from a net income of $10.3 million in Q1 2024 [3]. Business and Operational Activity - SIGA has outstanding Strategic National Stockpile orders totaling $94 million as of March 31, 2025, with expectations to deliver $70 million of these orders by the end of Q3 2025 [2][8]. - The company received a $26 million procurement order for IV TPOXX from the U.S. Government in March 2025 [9]. - In April 2025, SIGA delivered approximately $53 million of oral TPOXX and $9 million of IV TPOXX to the Strategic National Stockpile [9]. - TPOXX received regulatory approval in Japan for the treatment of smallpox and related diseases, marking a significant milestone for the company [9]. Capital Management - A special cash dividend of $0.60 per share was declared on April 8, 2025, to be paid on May 15, 2025 [6]. Assets and Liabilities - As of March 31, 2025, total assets were reported at $247.1 million, slightly up from $244.3 million as of December 31, 2024 [15][16]. - Current liabilities increased to $27.8 million from $25.3 million in the previous quarter [16]. Shareholder Information - The weighted average shares outstanding for basic and diluted calculations were 71.4 million for Q1 2025 [17].

Financial Data and Key Metrics Changes - Total revenues for Q4 2024 were $195 million, a decrease compared to the previous year due to lower NARCAN sales and Amtrac sales timing, partially offset by an adjusted EBITDA of $21 million, which is an increase of $18 million year-over-year [27] - Full-year 2024 total revenues were approximately $1.04 billion, roughly flat compared to the prior year, with total adjusted EBITDA of $183 million, a significant improvement from a negative $22 million in 2023 [29] - Operating expenses for the full year were $379 million, down $101 million or 21% year-over-year, reflecting cost actions taken in the second half of 2024 [30] Business Line Data and Key Metrics Changes - Total product sales for 2024 were $909 million, a slight decline from the previous year, with increased smallpox revenue offset by lower NARCAN sales [30] - NARCAN maintained a competitive price and market-leading distribution capabilities, with full-year volume consistent with 2023 levels, although prices were lower compared to 2023 [31] Market Data and Key Metrics Changes - The company distributed 11 million two-dose cartons (22 million doses) of NARCAN across the US and Canada, maintaining a market leadership position in the growing naloxone nasal spray market [18] - The naloxone market is expected to grow by mid to high single-digit rates, with NARCAN holding approximately 75% market share [50] Company Strategy and Development Direction - The company is executing a multi-year transformational plan aimed at stabilizing and ultimately transforming the business to generate long-term profitable growth [14] - Key goals for 2025 include strong profit follow-through from 2024, rebuilding the product pipeline, optimizing manufacturing operations, and strategic capital deployment for growth opportunities [20] Management's Comments on Operating Environment and Future Outlook - Management expressed a conservative approach to 2025 guidance due to potential shifts in government administration and timing uncertainties [22] - Despite a conservative outlook, management anticipates a strong first quarter of 2025, supported by the momentum from 2024 [40] Other Important Information - The company secured $550 million in MCM contract awards in 2024 and resolved legacy legal and quality issues, improving quality and compliance systems [19] - The company has a total liquidity of $200 million at the end of 2024, with net debt reduced to $601 million, a 21% decrease since the beginning of 2024 [36] Q&A Session Summary Question: Can you provide specifics on NARCAN guidance regarding volume and price? - Management noted that pricing stabilized in the second half of 2024, but a follow-through impact from previous price reductions is expected to affect full-year results [67][69] Question: How do you see adjusted EBITDA evolving in 2026 and beyond? - Management indicated that growth opportunities exist through diversification of the product portfolio and additional business development efforts [72][76] Question: What is the outlook for Kloxado in the market? - Management plans to leverage existing distribution capabilities to facilitate Kloxado's market entry and expects it to complement NARCAN in addressing fentanyl overdoses [84][86] Question: Is Kloxado already available within the NARCAN direct system? - Management confirmed that logistics are being worked out and expects Kloxado to be available within 30 to 60 days [93] Question: What are the expectations for near-term contract adjustments for BioDefense products? - Management anticipates continued execution of contracts and procurement orders from the US government, similar to the patterns seen in 2024 [99]

Table of Contents As filed with the Securities and Exchange Commission on April 2, 2024. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) (Primary Standard Industrial Classification Code Number) Delaware 2834 41-1505029 (I.R.S. Employer Identification Number) Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 (6 ...